Stock Market & Financial Investment News

News Breaks January 22, 2013 06:42 EDT TRIB Trinity Biotech downgraded to Neutral from Buy at Roth Capital Roth Capital downgraded Trinity Biotech due to valuation. Price target is $15.50. News For TRIB From The Last 14 Days Check below for free stories on TRIB the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. There are no results for TRIB Sign up for a free trial to see the rest of the stories you've been missing.